Table 7.
Bone and lipid markers
| Baseline | Mean % change from baseline (SD) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | End of study | ||
| Exemestane | |||||
| Bone | |||||
| n | 149 | 131 | 114 | 107 | 132 |
| BAP, μg/L | 32.4 (19.4) | 11.1 (30.9) | 4.4 (35.9) | 6.9 (40.8) | 13.7 (46.6) |
| NTx, nmola | 16.2 (7.7) | 4.63 (35.7) | 3.8 (37.5) | 8.4 (42.0) | 13.3 (47.2) |
| Lipid | |||||
| n | 149 | 131 | 114 | 107 | 144 |
| TC, mg/dL | 207.5 (34.9) | −2.0 (12.7) | −1.6 (12.7) | −1.4 (11.9) | −1.9 (15.3) |
| HDL-C, mg/dL | 57.1 (14.0) | −6.1 (15.5) | −7.3 (13.9) | −6.2 (13.7) | −8.6 (15.0) |
| LDL-C, mg/dL | 127.9 (32.4) | 4.9 (20.0) | 5.9 (19.6) | 4.9 (18.6) | 3.5 (23.6) |
| TG, mg/dL | 135.3 (62.8) | −12.3 (38.8) | −8.4 (41.0) | −13.3 (40.4) | −11.5 (38.0) |
| Anastrozole | |||||
| Bone | |||||
| n | 149 | 135 | 121 | 105 | 142 |
| BAP, μg/L | 35.3 (30.7) | 6.7 (28.2) | 2.8 (33.5) | 8.4 (41.2) | 12.8 (47.3) |
| NTx, nmola | 17.6 (9.8) | 2.2 (33.8) | 5.4 (36.2) | 1.8 (37.2) | 12.6 (47.7) |
| Lipid | |||||
| n | 149 | 135 | 121 | 105 | 148 |
| TC, mg/dL | 204.1 (35.3) | 4.1 (13.1) | 4.8 (13.7) | 5.9 (14.3) | 2.7 (15.1) |
| HDL-C, mg/dL | 58.5 (16.0) | 1.7 (14.4) | 3.7 (17.1) | 4.8 (15.0) | 1.5 (19.7) |
| LDL-C, mg/dL | 124.2 (32.5) | 5.8 (19.6) | 6.4 (18.7) | 7.9 (22.6) | 1.9 (22.1) |
| TG, mg/dL | 132.9 (67.5) | 1.9 (39.2) | 2.1 (46.8) | −0.5 (40.4) | 2.2 (42.6) |
BAP bone alkaline phosphatase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NTx type I collagen cross-linked N telopeptide, SD standard deviation, TC total cholesterol, TG triglyceride
aBone collagen equivalents/mmol creatinine